Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Capital Expenditures for 5 consecutive years, with $633000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 732.89% year-over-year to $633000.0, compared with a TTM value of $1.6 million through Dec 2025, up 466.06%, and an annual FY2025 reading of $1.6 million, up 466.06% over the prior year.
  • Capital Expenditures was $633000.0 for Q4 2025 at Kiniksa Pharmaceuticals International, up from $597000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $633000.0 in Q4 2025 and bottomed at -$32000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $132222.2, with a median of $55000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures crashed 112.75% in 2022, then soared 2495.65% in 2025.
  • Year by year, Capital Expenditures stood at $251000.0 in 2021, then plummeted by 112.75% to -$32000.0 in 2022, then skyrocketed by 275.0% to $56000.0 in 2023, then soared by 35.71% to $76000.0 in 2024, then soared by 732.89% to $633000.0 in 2025.
  • Business Quant data shows Capital Expenditures for KNSA at $633000.0 in Q4 2025, $597000.0 in Q3 2025, and $304000.0 in Q2 2025.